United States Drug Patent 7,179,483: Claim Scope, Expiration, Orange Book Status, and Oxybutynin Patent Landscape

U.S. Patent No. 7,179,483 protected a method of treating overactive bladder with transdermal oxybutynin while limiting exposure to N-desethyloxybutynin, the active metabolite associated with anticholinergic adverse effects. The patent focused on pharmacokinetic outcomes, not merely the composition of a patch or gel.

The patent issued on February 20, 2007, and its enforceable term ended in 2022 based on the underlying U.S. filing timeline. It therefore no longer creates an active U.S. patent barrier to generic or follow-on transdermal oxybutynin products. Its historical importance remains significant because it covered the pharmacokinetic rationale supporting Oxytrol and related transdermal products.

What does U.S. Patent 7,179,483 cover?

The patent covers a method of treating overactive bladder by administering transdermal oxybutynin to achieve a defined plasma exposure relationship between oxybutynin and an oxybutynin metabolite.

The core elements of claim 1 are:

The patient has overactive bladder.
Oxybutynin is administered through the skin.
The treatment is intended to minimize an anticholinergic or antimuscarinic adverse drug experience.
The formulation produces an oxybutynin-to-metabolite AUC ratio of approximately 0.5:1 to 5:1.
The dosage form is a topical formulation or transdermal patch.
The formulation may contain a permeation enhancer.

The relevant metabolite is principally N-desethyloxybutynin, also known as desethyloxybutynin. The patent treats reduced systemic exposure to that metabolite as the pharmacokinetic basis for reducing adverse events associated with oral oxybutynin.

What is the scope of independent claim 1?

Claim 1 is a method-of-treatment claim with both structural and pharmacokinetic limitations. It does not cover every oxybutynin patch or gel automatically. A potentially infringing product would need to satisfy the transdermal administration limitation and produce the specified exposure relationship under the claimed treatment conditions.

The claim is broad in dosage-form coverage. It includes:

Ointments
Lotions
Gels
Pastes
Mousses
Aerosols
Skin creams
Adhesive matrix patches
Liquid reservoir patches

The claim is also broad regarding the permeation enhancer. It does not require an enhancer, but expressly permits one.

How do the dependent claims narrow the patent?

The 43 dependent claims create several fallback positions:

Claim group	Principal limitation
Claims 2, 3, 25-28	Narrower oxybutynin-to-metabolite AUC ratios
Claims 4, 6-11	R- and S-enantiomer concentrations and ratios
Claims 5, 20-24	N-desethyloxybutynin as the relevant metabolite
Claims 12, 13, 20-24, 37-39	Peak metabolite concentration limits
Claims 14	Specified adverse-event categories
Claims 15, 16, 44	Permeation enhancers, including triacetin and urea
Claims 17-19	Racemic oxybutynin, R-oxybutynin, or S-oxybutynin
Claims 29-34, 42, 43	Six-hour, 24-hour, and steady-state plasma concentrations
Claims 35, 36	Comparative peak concentration and AUC relationships
Claims 40, 41	R-N-desethyloxybutynin AUC values

The narrowest claims depend on measured pharmacokinetic results. This creates a potential evidentiary issue: infringement analysis would generally require product-specific pharmacokinetic testing, a label review, or reliable evidence that the claimed plasma relationships necessarily result from the accused product.

What pharmacokinetic ratios does U.S. Patent 7,179,483 require?

The principal claimed relationship is the AUC ratio of oxybutynin to an oxybutynin metabolite.

Claim	Oxybutynin-to-metabolite AUC requirement
Claim 1	About 0.5:1 to about 5:1
Claim 2	About 1:1 to about 5:1
Claim 3	About 0.8:1 to about 1.5:1
Claim 25	About 0.5:1 to about 4:1
Claim 26	About 1:1 to about 5:1
Claim 27	About 0.8:1 to about 2.5:1
Claim 28	Claim 3 with N-desethyloxybutynin as the metabolite

Claims 8 and 9 focus on the ratio of R-N-desethyloxybutynin to R-oxybutynin. Claim 8 specifies a range of approximately 0.4:1 to 1.6:1, while claim 9 narrows the ratio to approximately 1:1.

The patent also claims exposure ceilings for N-desethyloxybutynin. The principal limits include:

Peak metabolite concentration below approximately 8 ng/mL.
Peak metabolite concentration below approximately 5 ng/mL.
Peak metabolite concentration from approximately 1 to 3 ng/mL.
A specific peak concentration of approximately 3 ng/mL.
R-N-desethyloxybutynin peak concentration below approximately 4 ng/mL.
R-N-desethyloxybutynin peak concentration from approximately 0.25 to 4 ng/mL.
R-N-desethyloxybutynin peak concentration of approximately 1.5 ng/mL.

These limitations distinguish the patent from a conventional formulation patent. The invention is defined partly by what happens in the patient after administration.

What formulations are protected by U.S. Patent 7,179,483?

The patent covers transdermal oxybutynin in both semisolid and patch formats.

Topical formulations

The claims expressly identify ointments, lotions, gels, pastes, mousses, aerosols, and creams. A topical gel that produces the claimed exposure profile could have fallen within the patent, subject to the remaining claim elements.

Transdermal patches

The claims identify:

Adhesive matrix patches
Liquid reservoir systems

This language is broader than a claim limited to a particular polymer, backing layer, adhesive, reservoir liquid, or patch geometry. The patent therefore could have applied to multiple patch architectures if the resulting plasma profile satisfied the claimed parameters.

Permeation enhancers

Claim 15 identifies the following enhancer categories:

Fatty acids
Fatty acid esters
Fatty alcohols
Fatty acid esters of lactic acid or glycolic acid
Glycerol triesters
Glycerol diesters
Glycerol monoesters
Triacetin
Short-chain alcohols
Urea
Mixtures of these materials

Claim 16 specifically covers triacetin. Claim 44 specifically covers urea.

The enhancer limitations are dependent limitations. A product does not need to contain triacetin or urea to fall within claim 1.

How does the patent treat R-oxybutynin and S-oxybutynin?

Claims 4 and 17-19 extend the patent to stereochemical forms of oxybutynin:

Racemic oxybutynin
R-oxybutynin
S-oxybutynin

The patent also claims separate enantiomeric metabolite relationships. Claim 7 requires an R-oxybutynin-to-S-oxybutynin AUC ratio of approximately 0.7:1. Claims 10 and 11 address the ratio of R-N-desethyloxybutynin to S-N-desethyloxybutynin.

Claims 35 and 36 add comparative pharmacokinetic limitations. Claim 35 requires the R metabolite's peak concentration and AUC to be approximately equal to or below the corresponding S metabolite values. Claim 36 requires R-oxybutynin and R-N-desethyloxybutynin to have approximately equal peak concentrations and AUCs.

These claims would have been particularly relevant to products using a single oxybutynin enantiomer or making stereochemical pharmacokinetic representations. They are no longer enforceable because the patent term has ended.

When did U.S. Patent 7,179,483 lose exclusivity?

The patent's U.S. patent term ended in 2022. The relevant term was governed by the 20-year period measured from the applicable nonprovisional filing date, subject to any patent-term adjustment or disclaimer recorded in the official patent file (U.S. Patent and Trademark Office, 2007).

The patent is therefore expired and cannot support a current U.S. infringement action. Any historical patent listing for Oxytrol does not restore enforceability after expiration.

Milestone	Date or status
U.S. patent issued	February 20, 2007
Patent type	Utility patent
Primary subject	Transdermal oxybutynin treatment method
Regulatory relevance	Oxytrol transdermal oxybutynin
U.S. term	Ended in 2022
Current enforceability	Expired
Current Paragraph IV exposure	None for this patent
Current biosimilar relevance	None

What was the Orange Book status of U.S. Patent 7,179,483?

U.S. Patent 7,179,483 was associated historically with the transdermal oxybutynin product Oxytrol. Oxytrol was approved by FDA as a transdermal oxybutynin system for overactive bladder and later became the first prescription drug for overactive bladder switched to nonprescription status in the United States (FDA, 2013).

The Orange Book relevance was tied to the listed drug and its transdermal delivery technology. Patent listings can support a Paragraph IV certification while the patent remains listed and unexpired. They do not create post-expiration exclusivity.

Oxytrol's historical patent estate included formulation and method-of-use rights. The distinction matters:

Formulation patents generally claim the patch, adhesive, reservoir, polymer, or delivery composition.
Method patents claim administration to achieve a therapeutic or pharmacokinetic result.
U.S. Patent 7,179,483 is primarily a method-of-treatment and pharmacokinetic patent.

The patent's expiration removes it as a current Orange Book barrier, regardless of whether historical Orange Book records continue to identify it in archived or commercial databases.

Which companies challenged oxybutynin transdermal exclusivity?

The principal competitive threat came from generic oxybutynin products and alternative branded transdermal formulations rather than biosimilar developers.

Relevant product categories included:

Product or category	Active ingredient	Delivery route	Competitive relationship
Oxytrol	Oxybutynin	Transdermal patch	Original reference product
Generic oxybutynin immediate release	Oxybutynin chloride	Oral	Lower-cost alternative, but different exposure profile
Generic oxybutynin extended release	Oxybutynin chloride	Oral	Competes for the same indication
Gelnique	Oxybutynin	Topical gel	Transdermal/topical alternative
Anturol	Oxybutynin	Topical gel	Alternative topical formulation
Ditropan XL	Oxybutynin chloride	Oral extended release	Branded oral competitor
Toviaz	Fesoterodine	Oral	Antimuscarinic alternative
Vesicare	Solifenacin	Oral	Antimuscarinic alternative
Myrbetriq	Mirabegron	Oral	Beta-3 adrenergic alternative

A Paragraph IV challenge to a method patent would have required a generic applicant to address listed claims and potentially argue noninfringement, invalidity, or unenforceability. For this patent, the pharmacokinetic limitations could create a noninfringement strategy if the generic label did not direct use of a product producing the claimed ratios or concentration thresholds.

Because the patent has expired, no current applicant needs to defeat it through a Paragraph IV certification.

What patent litigation affected U.S. Patent 7,179,483?

The main litigation significance of the patent was its potential use against transdermal oxybutynin products that sought to replicate the clinical and pharmacokinetic profile of Oxytrol. The claims could have supported an infringement theory based on:

The accused product's transdermal route.
Its use for overactive bladder.
Its product label or instructions.
Measured oxybutynin and N-desethyloxybutynin concentrations.
The relevant AUC and peak plasma concentration relationships.

Method-of-treatment claims also raise inducement issues. A manufacturer could face risk if its labeling specifically instructed users to administer the product in a manner satisfying the claimed treatment method. An unlabeled or non-instructed use would present a different analysis.

The patent does not provide a continuing basis for litigation. Any historical settlement, license, or consent order involving Oxytrol-related patents would need to be analyzed against the patent's expiration date. Post-expiration restrictions cannot extend the statutory patent term.

How strong was the patent estate for transdermal oxybutynin?

The estate was commercially meaningful before expiration because it addressed the principal differentiation between oral and transdermal oxybutynin: transdermal delivery could reduce first-pass metabolism and reduce exposure to N-desethyloxybutynin.

Its strengths were:

Broad coverage of topical and patch dosage forms.
Coverage of both racemic and individual enantiomeric oxybutynin.
Multiple fallback AUC ranges.
Peak concentration claims.
Six-hour, 24-hour, and steady-state concentration claims.
Coverage of common permeation enhancers.
Direct alignment with the pharmacology used to support transdermal administration.

Its limitations were:

Dependence on pharmacokinetic measurements.
Potential difficulty proving the required AUC ratios in routine commercial use.
Method-of-treatment rather than composition-only claim format.
Narrower dependent claims tied to particular concentration values.
Expiration in 2022.

The patent was stronger as a litigation complement to formulation patents than as a standalone permanent barrier. A formulation patent could be asserted from the product itself. This patent generally required proof that the product produced the claimed pharmacokinetic profile.

What generic entry risks exist after expiration?

Current U.S. generic entry risk is not constrained by U.S. Patent 7,179,483. The principal remaining barriers are commercial and regulatory:

FDA approval requirements for the dosage form.
Demonstration of bioequivalence or comparable performance.
Adhesion and wear characteristics for patches.
Skin irritation and sensitization testing.
Manufacturing consistency for drug loading and release.
Demonstration of preservative, adhesive, and enhancer stability.
Freedom-to-operate review of any later-expiring formulation or device patents.

For a topical or patch product, the relevant intellectual-property risk may shift from the expired method claim to later patents covering adhesive systems, backing layers, drug-in-adhesive matrices, reservoir designs, manufacturing processes, or particular formulations.

Does U.S. Patent 7,179,483 create biosimilar risk?

No. Oxybutynin is a synthetic small molecule, not a biologic. The relevant FDA pathway is an abbreviated new drug application or, depending on the product and regulatory circumstances, a full NDA pathway. Biosimilar approval under the Public Health Service Act does not apply.

The practical competitive issue is generic substitution and alternative small-molecule therapy, not biosimilar interchangeability.

What geographic coverage did the patent provide?

U.S. Patent 7,179,483 provided rights only in the United States. Foreign counterparts, if granted, would have had separate expiration dates, prosecution histories, claim scope, and legal status.

A global freedom-to-operate analysis must distinguish:

U.S. patent expiration.
European national or unitary rights.
Canadian rights.
Japanese rights.
Australian rights.
Country-specific regulatory exclusivity.
Local patent-term adjustment or supplementary protection regimes.

The U.S. expiration does not automatically terminate corresponding foreign rights, although many counterpart patents based on the same filing history may also have expired by 2022 or shortly thereafter.

Key Takeaways

U.S. Patent 7,179,483 claimed transdermal oxybutynin treatment that produced specified oxybutynin-to-metabolite exposure ratios.
The key metabolite was N-desethyloxybutynin.
Claim 1 covered topical formulations and adhesive matrix or liquid reservoir patches.
Dependent claims addressed AUC ratios, peak concentrations, stereoisomers, permeation enhancers, and steady-state plasma levels.
The patent's commercial relevance was closely tied to Oxytrol and the pharmacokinetic rationale for transdermal oxybutynin.
The patent expired in 2022 and is not a current U.S. barrier to generic entry.
No biosimilar pathway applies because oxybutynin is a small-molecule drug.
Current diligence should focus on later formulation, device, manufacturing, and regulatory barriers rather than this expired method patent.

FAQs

Can an oxybutynin gel still infringe U.S. Patent 7,179,483?

No current infringement liability arises from this patent because its U.S. term has expired. Before expiration, a gel could have implicated the patent if it was used for overactive bladder and produced the claimed pharmacokinetic profile.

Did the patent cover oral oxybutynin?

No. The claims require a transdermal formulation. Oral immediate-release and extended-release oxybutynin products fall outside the express route limitation.

Is N-desethyloxybutynin the same as oxybutynin chloride?

No. Oxybutynin chloride is the drug salt used in many products. N-desethyloxybutynin is a metabolite formed after oxybutynin metabolism and is the principal metabolite addressed by the patent.

Could a product avoid the claims by using R-oxybutynin?

Not necessarily. Claims 4, 17, and 18 expressly address R-oxybutynin. The patent also includes stereoselective metabolite and AUC claims.

Is Oxytrol still protected by this patent outside the United States?

The U.S. patent has expired. Foreign patent rights must be assessed country by country because counterpart patents have separate terms and legal statuses.

References

U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter drug for overactive bladder. https://www.fda.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/
U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,179,483, Methods of reducing adverse effects associated with oxybutynin therapy. https://patents.google.com/patent/US7179483
U.S. Patent and Trademark Office. (2024). Patent term calculator and patent term adjustment resources. https://www.uspto.gov/ 马会

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
Australia	2010200418	⤷ Start Trial
Australia	2012216593	⤷ Start Trial
Australia	5378201	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,179,483

Summary for Patent: 7,179,483